Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.
Mike J. Pishvaian, MD, PhD
Advertisement
Mike J. Pishvaian, MD, PhD, is director of Gastrointestinal, Developmental Therapeutics and Clinical Research Programs and an associate professor of oncology at Johns Hopkins Medicine in Baltimore, Maryland.
Articles by Mike J. Pishvaian, MD, PhD
Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.
Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the prevalence of RAS mutations in pancreatic ductal adenocarcinoma.
Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, detail the continued interest in RAS inhibition for pancreatic ductal adenocarcinoma.
Michael Jon Pishvaian, MD, PhD, discusses the clinical implications of the phase 3 RATIONALE 306 trial and the adverse effects associated with immunotherapy in patients with advanced esophageal squamous cell carcinoma.
Michael J. Pishvaian, MD, PhD, discusses the FDA approval of the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for the treatment of patients with hepatocellular carcinoma (HCC).
Advertisement
Latest Updated Articles
Dr. Pishvaian on FDA Approval of Atezolizumab Plus Bevacizumab in HCCPublished: May 29th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5